Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Ermenegildo Zegna NV
ZGN
5
Precision Drilling
PDS
US OptionsDetailed Quotes
SCPH250516P5000
- 2.56
- 0.000.00%
15min DelayClose May 13 16:00 ET
0.00High0.00Low
2.56Open2.56Pre Close0 Volume101 Open Interest5.00Strike Price0.00Turnover0.00%IV-5.17%PremiumMay 16, 2025Expiry Date2.68Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.88Leverage Ratio--Theta--Rho--Eff Leverage--Vega
scPharmaceuticals Stock Discussion
Sign in to post a comment
$scPharmaceuticals (SCPH.US)$ So now that they have another quarter under their belt of selling. Im kinda lookin for earning to be yet another improvement/growth! No telling what surprises may be in there as well? (( Good or Bad )) But i can say im actually lookin for it to be pretty good! But wont know that until post market tomorrow for sure! 5/14![]()
3
2
$scPharmaceuticals (SCPH.US)$ why drop dip?
$scPharmaceuticals (SCPH.US)$ scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million
Cash and cash equivalents of $75.7 million as of December 31, 2024
U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overloa...
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million
Cash and cash equivalents of $75.7 million as of December 31, 2024
U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overloa...
3
2
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...
48
28
4
$scPharmaceuticals (SCPH.US)$ Reuters·
ScPharmaceuticals Inc: Furoscix Is Expected to Be Available for Chronic Kidney Disease Patients in April 2025
ScPharmaceuticals Inc: Furoscix Is Expected to Be Available for Chronic Kidney Disease Patients in April 2025
4
14
$scPharmaceuticals (SCPH.US)$ Reuters
·1 min ago
ScPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix® Indication to Include the Treatment of Edema in Patients With Chronic Kidney Disease
·1 min ago
ScPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix® Indication to Include the Treatment of Edema in Patients With Chronic Kidney Disease
2
$scPharmaceuticals (SCPH.US)$
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
Thursday, 6th March at 4:01 pm
FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome
FUROSCIX is expected to be available ...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
Thursday, 6th March at 4:01 pm
FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome
FUROSCIX is expected to be available ...
2
No comment yet
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
B_jammin : Gotta love a little gamble.
Trytosaveabit OP B_jammin : Indeed! As long as you use risk management! Nothing wrong at all! Hehehe GL